Skinner P S, Furney S K, Kleinert D A, Orme I M
Department of Microbiology, Colorado State University, Fort Collins 80523, USA.
Antimicrob Agents Chemother. 1995 Mar;39(3):750-3. doi: 10.1128/AAC.39.3.750.
In this study the compounds levofloxacin and sparfloxacin, as well as three experimental compounds (AMQ2, AMQ4, and AMQ5), were compared with isoniazid and rifabutin in terms of their capacity to inhibit the intracellular growth of the drug-susceptible Mycobacterium tuberculosis strain Erdman and the isoniazid-resistant katG gene-negative strain 24 within monolayers of mouse bone marrow-derived macrophages. Both levofloxacin and sparfloxacin, as well as compound AMQ4, had substantial activity in this physiologically relevant model, further confirming the potential usefulness of this class of compounds in the therapy of tuberculosis.
在本研究中,将左氧氟沙星和司帕沙星这两种化合物,以及三种实验性化合物(AMQ2、AMQ4和AMQ5),就其抑制药物敏感的结核分枝杆菌埃尔德曼菌株和异烟肼耐药的katG基因阴性菌株24在小鼠骨髓来源巨噬细胞单层内细胞内生长的能力,与异烟肼和利福布汀进行了比较。左氧氟沙星、司帕沙星以及化合物AMQ4在这个生理相关模型中均具有显著活性,进一步证实了这类化合物在结核病治疗中的潜在效用。